Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at the 2021 ASCRS ASOA Annual Meeting

July 19, 2021 12:00 UTC

 

Marks Allegro’s Second Exploratory Study of ALG-1007 in Dry Eye Disease

 

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics LLC a privately held biopharmaceutical company focused on the development of novel oxidative stress-stabilizers for the treatment of ocular diseases, today announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting being held July 23-27 in Las Vegas, NV.

On Thursday, July 22, Allegro’s President and CEO, Vicken Karageozian, M.D., will present at Eyecelerator™ during its “Dry Eye: The Need for Innovation” session. Then, on Saturday, July 24, Eric D. Donnenfeld, M.D., will present full study results of the company’s second ALG-1007 ex-U.S. clinical trial for DED at ASCRS ASOA.

“Allegro is very much looking forward to participating in the first live Eyecelerator meeting and to sharing the results of a randomized, double masked, vehicle-controlled clinical trial of ALG-1007 for the treatment of dry eye disease,” said Vicken Karageozian, M.D., President and CEO of Allegro Ophthalmics. “The new data will provide insights into the formulation, efficacy, tolerability, and safety of the experimental topical eye drop ALG-1007 in patients with dry eye disease, and underscores Allegro’s commitment to developing innovative treatments that bring meaningful therapeutic benefits to patients.”

The corporate and scientific presentations are scheduled as follows:

Thursday, July 22: 3:25-4:15 PM
Eyecelerator, Mandalay Bay South Convention Center
Oxidative Stress Stabilizers for the Treatment of Ocular Diseases
Vicken Karageozian, M.D.

Saturday, July 24 1:40-1:45 PM
ASCRS ASOA, Mandalay Bay Convention Center, MBCR-Level 2, Surf EF
Prospective, Randomized, Double-masked, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Topical Risuteganib (ALG-1007) for the Treatment of Dry Eye Disease.
Eric D. Donnenfeld, M.D.

All educational content of the ASCRS ASOA Annual Meeting is planned by its program committee, and ASCRS ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.

About Allegro Ophthalmics, LLC

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro’s lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD. A U.S. Phase 2a study with risuteganib in less advanced dry AMD met its primary endpoint of vision recovery. Expanding its oxidative stress-stabilizing portfolio, Allegro has developed ALG-1007 for topical use in dry eye disease. ALG-1007 demonstrated promising results in two ex-U.S. studies in humans. For more information, visit www.allegroeye.com.

Risuteganib (Luminate®) and ALG-1007 are investigational drugs and are not approved for commercial sale.

Luminate® is a registered trademark of Allegro Ophthalmics, LLC.

Contacts

Michele Gray
Gray Communications, LLC
(917) 449-9250
michele@mgraycommunications.com

 
 

Source: Allegro Ophthalmics, LLC

Back to news